BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
read more...
Feb 29, 2024
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
read more...
Feb 28, 2024
BeiGene to Present at Upcoming Investor Conferences
read more...
Feb 27, 2024
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
read more...
Feb 26, 2024
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
read more...
Feb 26, 2024
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
read more...
Jan 23, 2024
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
read more...
Dec 22, 2023
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
read more...
Dec 21, 2023
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
read more...
Nov 29, 2023
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
read more...
Nov 28, 2023
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
read more...
Nov 21, 2023
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
read more...
Nov 17, 2023
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
read more...
Nov 09, 2023
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
read more...
Nov 08, 2023
BeiGene to Present at the Jefferies London Healthcare Conference
read more...
Oct 20, 2023
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
read more...
Oct 17, 2023
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
read more...
Oct 17, 2023
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
read more...
Oct 16, 2023
BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
read more...
Oct 13, 2023
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
read more...
